Sign in Register

Drug class

Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC

The phrase "Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC" represents a composite clinical and formulary categorization rather than a single pharmacologic drug class. Read more about Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC

34 drugs in this class 33 manufacturers

Related classes & indications

Proton Pump InhibitorsGastrointestinal · 219 prescription drugs Histamine-2 Receptor Antagonists (H2 Antagonists)Gastrointestinal · 78 prescription drugs Chronic Idiopathic ConstipationTop indication · 37 prescription drugs

Showing 10–18 of 34 drugs

Sort

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

PAR HEALTH USA,

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

DR.REDDY'S LAB

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

GSMS, INC.

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

DIRECT RX

PRUCALOPRIDE (prucalopride succinate)

GI STIMULANTS · CHRONIC IDIOPATHIC CONSTIPATION

ANI PHARMACEUTI

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

SUN PHARMACEUTI

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

PROFICIENT RX L

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

ZYDUS PHARMACEU

LUBIPROSTONE

IRRITABLE BOWEL SYNDROME AGENTS · CONSTIPATION PREDOMINANT IRRITABLE BOWEL SYNDROME ·+2

DASH/NATCO PHAR

Filter & compare in the drug finder → Opens the drug finder with Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC preselected. Add indication or manufacturer filters there.

About Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC.

The phrase "Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC" represents a composite clinical and formulary categorization rather than a single pharmacologic drug class.

It encompasses several distinct mechanistic classes—most notably intestinal secretagogues like guanylate cyclase-C agonists and chloride channel activators, 5-HT4 receptor agonists, and peripherally acting mu-opioid receptor antagonists.

Functioning to increase intestinal fluid secretion, accelerate gastrointestinal transit, or reverse opioid-induced bowel dysfunction, these medications provide targeted symptom management beyond conventional laxatives.

They are indicated for adults with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC).

nih.gov
The phrase "Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC" represents a composite clinical and formulary categorization rather than a single pharmacologic drug class It encompasses several distinct mechanistic classes—most notably intestinal secretagogues like guanylate cyclase-C agonists and chloride channel activators, 5-HT4 receptor agonists, and peripherally acting mu-opioid receptor antagonists Functioning to increase intestinal fluid secretion, accelerate gastrointestinal trans...
nih.gov
The phrase "Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC" represents a composite clinical and formulary categorization rather than a single pharmacologic drug class
iffgd.org
The phrase "Agents to Treat Chronic Idiopathic Constipation/IBS-C/OIC" represents a composite clinical and formulary categorization rather than a single pharmacologic drug class They are indicated for adults with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC)
youandconstipation.org
It encompasses several distinct mechanistic classes—most notably intestinal secretagogues like guanylate cyclase-C agonists and chloride channel activators, 5-HT4 receptor agonists, and peripherally acting mu-opioid receptor antagonists Functioning to increase intestinal fluid secretion, accelerate gastrointestinal transit, or reverse opioid-induced bowel dysfunction, these medications provide targeted symptom management beyond conventional laxatives
ahdbonline.com
It encompasses several distinct mechanistic classes—most notably intestinal secretagogues like guanylate cyclase-C agonists and chloride channel activators, 5-HT4 receptor agonists, and peripherally acting mu-opioid receptor antagonists They are indicated for adults with chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC)
pharmacytimes.com
Functioning to increase intestinal fluid secretion, accelerate gastrointestinal transit, or reverse opioid-induced bowel dysfunction, these medications provide targeted symptom management beyond conventional laxatives